Intra-Cellular Therapies Inc [ITCI] stock is trading at $131.28, up 2.40%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ITCI shares have gain 2.11% over the last week, with a monthly amount glided 3.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intra-Cellular Therapies Inc [NASDAQ: ITCI] stock has seen the most recent analyst activity on February 24, 2025, when Mizuho downgraded its rating to a Neutral and also revised its price target to $132 from $140. Previously, Canaccord Genuity downgraded its rating to Hold on January 31, 2025, and elevated its price target to $132. On September 06, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $92 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $83 on January 03, 2024. TD Cowen initiated its recommendation with a Outperform and recommended $75 as its price target on December 11, 2023. Morgan Stanley started tracking with a Overweight rating for this stock on April 20, 2023, and assigned it a price target of $80. In a note dated August 22, 2022, Goldman downgraded an Neutral rating on this stock and revised its target price from $64 to $49.
Intra-Cellular Therapies Inc [ITCI] stock has fluctuated between $63.30 and $129.00 over the past year. Currently, Wall Street analysts expect the stock to reach $105.5 within the next 12 months. Intra-Cellular Therapies Inc [NASDAQ: ITCI] shares were valued at $131.28 at the most recent close of the market. An investor can expect a potential drop of -19.64% based on the average ITCI price forecast.
Analyzing the ITCI fundamentals
Intra-Cellular Therapies Inc [NASDAQ:ITCI] reported sales of 680.85M for the trailing twelve months, which represents a growth of 50.81%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.17%, Pretax Profit Margin comes in at -0.11%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.07 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 131.20 points at the first support level, and at 131.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 131.35, and for the 2nd resistance point, it is at 131.43.
Ratios To Look Out For
For context, Intra-Cellular Therapies Inc’s Current Ratio is 6.36. As well, the Quick Ratio is 6.23, while the Cash Ratio is 1.49. Considering the valuation of this stock, the price to sales ratio is 20.50, the price to book ratio is 12.14.
Transactions by insiders
Recent insider trading involved Mates Sharon, Chairman and CEO, that happened on Dec 04 ’24 when 51000.0 shares were sold. Chairman and CEO, Mates Sharon completed a deal on Dec 05 ’24 to sell 51697.0 shares. Meanwhile, Officer Mates Sharon bought 51697.0 shares on Dec 05 ’24.
